Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Saved in:

Bibliographic Details
Main Authors:	Jesse Haramati, Fabiola Solorzano-Ibarra, Dallas B. Flies
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	ICI Immunotherapy cancer tumor personalized & precision medicine checkpoint blockade (ICB) therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings
by: Maria Meira, et al.
Published: (2024-12-01)

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
by: Lin Zhang, et al.
Published: (2025-01-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
by: Yuxiang Huang, et al.
Published: (2025-01-01)

Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
by: Hafiza Kashaf Tariq, et al.
Published: (2025-01-01)

Integrated multi-omics analysis reveals clinical significance of hepatocyte nuclear factor-1β in tumor immune microenvironment, immunotherapy and prognostic prediction for colon adenocarcinoma
by: Fushan Gao, et al.
Published: (2024-12-01)

Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
by: Said SS, et al.
Published: (2025-01-01)

Sequentially Activated Smart DNA Nanospheres for Photoimmunotherapy and Immune Checkpoint Blockade
by: Yu Chen, et al.
Published: (2025-01-01)

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
by: Maximilian Riedel, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade
by: Victoria E. Stefan, et al.
Published: (2024-11-01)

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Electrochemical sensors for the detection of immune checkpoint related proteins and their role in cancer companion diagnostics
by: Louise Barnaby, et al.
Published: (2025-03-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
by: Fei Yang, et al.
Published: (2025-01-01)

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
by: Zheng Wang, et al.
Published: (2024-12-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Editorial: Tertiary lymphoid structures (TLS) in the tumor immune microenvironment
by: Xinbo Gao, et al.
Published: (2025-01-01)

Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
by: Tianqing Wang, et al.
Published: (2025-02-01)

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer
by: Xumin Zhou, et al.
Published: (2025-02-01)

The success of the tumor immunotherapy: neutrophils from bench to beside
by: Meng Zhu, et al.
Published: (2025-01-01)

Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
by: Xue Wang, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)